BioCentury | Oct 17, 2011
Emerging Company Profile

KalVista: Filling the VEGF void

...of DME. At least two other companies have plasma kallikrein inhibitor programs for macular edema. ActiveSite Pharmaceuticals Inc....
...its focus. Vantia has Phase II programs for nocturia and dysmenorrhea. Companies and Institutions Mentioned ActiveSite Pharmaceuticals Inc....
BioCentury | Apr 11, 2011
Clinical News

ASP-440 ophthalmic data

...inhibitor also did not alter blood glucose or body weight. Data were published in Diabetes. ActiveSite...
BioCentury | Oct 24, 2005
Company News

Ensemble Discovery, Fujitsu Ltd. deal

...of automated docking and molecular modeling software to Ensemble. Ensemble also received access to Fujitsu's ActiveSite...
BioCentury | Feb 28, 2005
Company News

NeurAxon, Fujitsu Ltd. deal

...modeling software from Fujitsu's Fujitsu America BioSciences Group (Westwood, Mass.). The deal also includes Fujitsu's ActiveSite...
Items per page:
1 - 4 of 4
BioCentury | Oct 17, 2011
Emerging Company Profile

KalVista: Filling the VEGF void

...of DME. At least two other companies have plasma kallikrein inhibitor programs for macular edema. ActiveSite Pharmaceuticals Inc....
...its focus. Vantia has Phase II programs for nocturia and dysmenorrhea. Companies and Institutions Mentioned ActiveSite Pharmaceuticals Inc....
BioCentury | Apr 11, 2011
Clinical News

ASP-440 ophthalmic data

...inhibitor also did not alter blood glucose or body weight. Data were published in Diabetes. ActiveSite...
BioCentury | Oct 24, 2005
Company News

Ensemble Discovery, Fujitsu Ltd. deal

...of automated docking and molecular modeling software to Ensemble. Ensemble also received access to Fujitsu's ActiveSite...
BioCentury | Feb 28, 2005
Company News

NeurAxon, Fujitsu Ltd. deal

...modeling software from Fujitsu's Fujitsu America BioSciences Group (Westwood, Mass.). The deal also includes Fujitsu's ActiveSite...
Items per page:
1 - 4 of 4